Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05999240 · ClinicalTrials.gov registry record · Phase 2
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
A Phase 2 study of Autism Spectrum Disorder, sponsored by New York State Psychiatric Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT05999240 is a Phase 2 study of Autism Spectrum Disorder that is actively recruiting participants, run by New York State Psychiatric Institute. The registered enrollment target is 30 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (78% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05999240, a Phase 2 study of Autism Spectrum Disorder, is actively recruiting participants, sponsored by New York State Psychiatric Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
This Phase 2 study examines the safety, tolerability, and preliminary efficacy of pimavanserin in individuals with Autism Spectrum Disorder. Male or female participants aged 16 to 40 years of age will be randomized to receive single doses of either placebo or pimavanserin in this randomized, placebo-controlled, cross-over designed study, followed by open label extension.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID]
Study Locations (2)
Kansas
- Wakarusa Research Facility - Lawrence
New York
- Center for Autism and the Developing Brain - White Plains
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-10-01 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05999240
The ClinicalTrials.gov registry entry for NCT05999240 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (78% lower). The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05999240 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Kansas, New York.
Frequently Asked Questions
What is clinical trial NCT05999240 about?
NCT05999240 is a clinical study titled "Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder". This Phase 2 study examines the safety, tolerability, and preliminary efficacy of pimavanserin in individuals with Autism Spectrum Disorder. Male or female participants aged 16 to 40 years of age will be randomized to receive single doses of either placebo or pimavanserin in this randomized, placebo...
What is the current status of trial NCT05999240?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-10-01. Estimated completion is 2026-12-31.
What conditions does trial NCT05999240 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder.
What interventions are being tested in trial NCT05999240?
The interventions under investigation include: Placebo (DRUG), Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID] (DRUG).
Who is sponsoring clinical trial NCT05999240?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05999240 being conducted?
This trial has 2 study locations across Kansas, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial
RECRUITING · Phase 2
-
Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium
RECRUITING · Phase 2
-
Optimizing Outcomes for Young Autistic Children
RECRUITING · Phase 2
-
Trial of Zolpidem for Sleep in Children With Autism
RECRUITING · Phase 2
-
Telehealth-Enabled Versus In-Person Parent-Mediated Behavioral Treatment for Challenging Behaviors in Children With ASD
RECRUITING · Phase 2
-
A Study of Esomeprazole in Children With Autism
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.